. 2019 Dec 23;5(4):00056-2019. doi: 10.1183/23120541.00056-2019

TABLE 3.

Efficacy of azithromycin on quality of life in severe asthma at end of treatment (observed data only)

	Placebo	Azithromycin	p-value^#
AQLQ mean score	5.45 (5.19–5.70)^¶	5.61 (5.41–5.82)⁺	0.029
AQLQ Activity domain	5.55 (5.29–5.81)^¶	5.70 (5.49–5.90)⁺	0.063
AQLQ Symptoms domain	5.28 (5.02–5.55)^§	5.49 (5.28–5.71)^ƒ	0.031
AQLQ Emotions domain	5.37 (5.03–5.71)^§	5.57 (5.29–5.85)^ƒ	0.017
AQLQ Environment domain	5.76 (5.49–6.02)^§	5.68 (5.46–5.91)^ƒ	0.262

Data are presented as mean (95% CI) unless otherwise stated. No significant interaction was present. AQLQ: Asthma Quality of Life Questionnaire. ^#: ANCOVA adjusted for baseline measurement, phenotype (noneosinophilic/eosinophilic asthma) and phenotype–treatment interaction; ^¶: n=95; ⁺: n=113; ^§: n=96; ^ƒ: n=115.